ArticleJournal of Cancer2013
TGF-β2: A Novel Target of CD44-Promoted Breast Cancer Invasion.
Article in Journal of Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- CD44 knockdown and TGF‑β inhibition modulate cell proliferation and invasion in claudin‑low breast cancer cells.Oncology reports · 2026Article
- Update on the Association of CD44 Expression with Esophageal Squamous Cell Carcinoma Invasion.Reports of biochemistry & molecular biology · 2025Article
- Review
- Targeting Cell Death Mechanism Specifically in Triple Negative Breast Cancer Cell Lines.International journal of molecular sciences · 2022Article
- SNX5 suppresses clear cell renal cell carcinoma progression by inducing CD44 internalization and epithelial-to-mesenchymal transition.Molecular therapy oncolytics · 2022Article
- Review
- Recent advances in photothermal therapy-based multifunctional nanoplatforms for breast cancer.Frontiers in chemistry · 2022Review
- SIRT1, a novel transcriptional downstream target of CD44, linking its deacetylase activity to tumor cell invasion/metastasis.Frontiers in oncology · 2022Review
- PCF11, a Novel CD44-Downstream Transcriptional Target, Linking Its 3'-End Polyadenylation Function to Tumor Cell Metastasis.Frontiers in oncology · 2022Review
- Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.Theranostics · 2022Article
- The differentiation state of the Schwann cell progenitor drives phenotypic variation between two contagious cancers.PLoS pathogens · 2021Article
- KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion.Journal of cellular and molecular medicine · 2021Review
- Evaluation of CD44 and TGF-B Expression in Oral Carcinogenesis.Journal of dentistry (Shiraz, Iran) · 2021Article
- Proteolytic Processing of CD44 and Its Implications in Cancer.Stem cells international · 2021Review
- Distinct phenotypes of cancer cells on tissue matrix gel.Breast cancer research : BCR · 2020Article
- CD44 mediates stem cell mobilization to damaged lungInternational journal of medical sciences · 2020Article
- OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition.Cancer management and research · 2019Article
- Osteopontin controls immunosuppression in the tumor microenvironment.The Journal of clinical investigation · 2018Article
- The biology and role of CD44 in cancer progression: therapeutic implications.Journal of hematology & oncology · 2018Review
- A correlation study of the expression of HA-CD44st and HER-2 in breast cancer.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have developed a tetracycline (tet)-off regulated expression of CD44s gene in the breast cancer (BC) cell line MCF-7 (B5 clone) and identified TGF-β2 (Transforming Growth Factor beta-2; 3 fold induction) as a potential CD44-downstream transcriptional target by microarray analysis. To further validate this finding, the same RNA samples, used for microarray analysis and their corresponding protein lysates, collected from the BC cell line MCF-7-B5, were examined for CD44 expression in the presence of HA. Our results showed that TGF-β2 mRNA levels were significantly elevated following the removal of tetracycline at 18, 24, and 48 h post-HA stimulation compared to the parental cells. Furthermore, the TGF-β2 precursor protein increased in a time-dependent pattern upon HA-stimulation and in the absence of tetracycline. More interestingly, inhibition of CD44 gene by RNAi method decreased TGF-β2 expression upon HA-stimulation, and subsequently inhibited BC cell invasion in vitro. In addition to identifying TGF-β2 as a target for HA/CD44 signaling, this data suggests that ATF/CREB might be a potential transcription factor linking HA/CD44 activation to TGF-β2 transcription and additional experiments are required for a better understanding of the molecular mechanisms underpinning the novel function of the CD44/ TGF-β2 signaling pathway in breast cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.